Dr. Nagla Abdel Karim
@naglaakarimmd.bsky.social
American Board Certified Medical Oncologist who specializes in Thoracic Oncology, Phase I & Global Oncology #MedSky #MedTwitter
bsky.app
October 17, 2025 at 10:08 PM
More to go with our @iaslc.bsky.social Podcast in Arabic!
In this episode of #LungCancerConsidered in Arabic, @naglaakarimmd.bsky.social talks with Dr. Asrar AlAhmadi and Dr. Maya Khalil about the experiences and career paths of Arabic women in thoracic oncology.
🎧 Listen now: bit.ly/ArabWomenTO
🎧 Listen now: bit.ly/ArabWomenTO
LCC in Arabic: Arabic Women’s Voices in Thoracic Oncology | IASLC
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Asrar AlAhmadi and Dr. Maya ...
bit.ly
September 6, 2025 at 11:35 AM
More to go with our @iaslc.bsky.social Podcast in Arabic!
I am honored to present today 9/6 our oligometastatic subcommittee updates @IASLC #wclc2025 workshop 2:30 PM WS14 From Guidelines to Implementation in NSCLC: Pertinent Considerations of Adherence to Consensus Standards of Care in Clinical Practice
Location: Room 09
Location: Room 09
September 6, 2025 at 11:34 AM
I am honored to present today 9/6 our oligometastatic subcommittee updates @IASLC #wclc2025 workshop 2:30 PM WS14 From Guidelines to Implementation in NSCLC: Pertinent Considerations of Adherence to Consensus Standards of Care in Clinical Practice
Location: Room 09
Location: Room 09
It was a great pleasure to be part of the SCLC panel at “Call to Action” New York Summit.
March 22, 2025 at 1:53 PM
It was a great pleasure to be part of the SCLC panel at “Call to Action” New York Summit.
It’s always a great pleasure to be part of @iaslc.bsky.social #TTLC25
February 22, 2025 at 7:59 PM
It’s always a great pleasure to be part of @iaslc.bsky.social #TTLC25
It has been a great pleasure to present “Immunotherapy and Inflammation: Impact on Cardiovascular Health” #ACCCardioOnc! Cardio-Oncology Conference in DC.
February 16, 2025 at 3:57 PM
It has been a great pleasure to present “Immunotherapy and Inflammation: Impact on Cardiovascular Health” #ACCCardioOnc! Cardio-Oncology Conference in DC.
Stay Tuned for the updates in Thoracic Neuroendocrine Tumors #NETChatter
February 10, 2025 at 6:24 PM
Stay Tuned for the updates in Thoracic Neuroendocrine Tumors #NETChatter
Lung Cancer Alliance in Arabic-Speaking MENA (LCAM).
This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA
This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA
December 21, 2024 at 7:47 PM
Lung Cancer Alliance in Arabic-Speaking MENA (LCAM).
This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA
This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
December 4, 2024 at 9:53 PM
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.
November 25, 2024 at 12:39 AM
It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.
Reposted by Dr. Nagla Abdel Karim
Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness
An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.
www.wral.com
November 22, 2024 at 11:54 PM
Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
www.wral.com/lifestyle/he...
@younglungcancer.bsky.social
Reposted by Dr. Nagla Abdel Karim
Authors discuss a few of the many, many challenges in trying to make "decentralized" clinical trials happen
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Ensuring Virtual Vigilance in Decentralized Clinical Trials
This Viewpoint discusses the increased use of decentralized clinical trials (DCTs) to improve efficiency in health research, highlights a number of risks to research rigor inherent in DCTs, and sugges...
jamanetwork.com
November 20, 2024 at 6:57 PM
Authors discuss a few of the many, many challenges in trying to make "decentralized" clinical trials happen
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Dr. Nagla Abdel Karim
Superb opinion piece on PCI in SCLC: do we need it in the IO era?
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...
November 16, 2024 at 9:26 PM
Superb opinion piece on PCI in SCLC: do we need it in the IO era?
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...
www.jto.org/article/S155...
It is pretty feasible to personalize therapy for small cell lung cancer.
It is about time to improve the predictive biomarkers & novel therapies for SCLC.
It is pretty feasible to personalize therapy for small cell lung cancer.
It is about time to improve the predictive biomarkers & novel therapies for SCLC.
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
To evaluate whether the addition of a poly (ADP-ribose) polymerase inhibitor (PARPi)
talazoparib to maintenance immune checkpoint inhibitor (ICI) atezolizumab following
frontline chemoimmunotherapy im...
www.jto.org
November 13, 2024 at 6:14 PM
www.jto.org/article/S155...
It is pretty feasible to personalize therapy for small cell lung cancer.
It is about time to improve the predictive biomarkers & novel therapies for SCLC.
It is pretty feasible to personalize therapy for small cell lung cancer.
It is about time to improve the predictive biomarkers & novel therapies for SCLC.